摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-(3-溴苯基)异恶唑 | 7064-33-7

中文名称
5-(3-溴苯基)异恶唑
中文别名
5-(3-溴苯基)异唑;5-(3-溴苯基)异噁唑
英文名称
5-(3-bromophenyl)isoxazole
英文别名
5-(3-bromo-phenyl)-isoxazole;5-(m-Bromphenyl)-isoxazol;5-m-Bromphenylisoxazol;5-(3-bromophenyl)-1,2-oxazole
5-(3-溴苯基)异恶唑化学式
CAS
7064-33-7
化学式
C9H6BrNO
mdl
——
分子量
224.057
InChiKey
RVTONCSWDXJDIN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    66 °C
  • 沸点:
    320.7±17.0 °C(Predicted)
  • 密度:
    1.524±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    26
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 危险品标志:
    Xi
  • 海关编码:
    2934999090
  • 包装等级:
    III
  • 危险类别:
    6.1
  • 危险性防范说明:
    P233,P260,P261,P264,P270,P271,P280,P301+P310,P302+P352,P304,P304+P340,P305+P351+P338,P312,P321,P330,P332+P313,P337+P313,P340,P362,P403,P403+P233,P405,P501
  • 危险品运输编号:
    2811
  • 危险性描述:
    H301,H315,H319,H335

SDS

SDS:1bbd0494c46140b9d4b0a1566a04e032
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 5-(3-Bromophenyl)isoxazole
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 5-(3-Bromophenyl)isoxazole
CAS number: 7064-33-7

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H6BrNO
Molecular weight: 224.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    描述:
    5-(3-溴苯基)异恶唑 在 potassium osmate(VI) dihydrate 、 sodium periodate1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物三乙胺 作用下, 以 四氢呋喃异丙醇 为溶剂, 反应 2.0h, 生成 3-(isoxazol-5-yl)benzaldehyde
    参考文献:
    名称:
    [EN] INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF
    [FR] INHIBITEURS DE LA GLYCOGÈNE SYNTHASE 1 (GYS1) ET LEURS MÉTHODES D'UTILISATION
    摘要:
    本文提供了公式(I')的化合物或其立体异构体或互变异构体,或任何其药学上可接受的盐,其中Y2,Y3,L1,L2,X1,X2,X3,X4,X5,Q1,R1,R2,Rk,Rm和Rn的定义在本文其他部分中已经说明。本文还提供了制备公式(F)化合物的方法。本文还提供了抑制GYS1的方法以及治疗需要该方法的个体中的GYS1介导的疾病,障碍或状况的方法。
    公开号:
    WO2022198196A1
  • 作为产物:
    描述:
    3'-溴苯乙酮盐酸羟胺 作用下, 以 甲醇 为溶剂, 反应 72.0h, 生成 5-(3-溴苯基)异恶唑
    参考文献:
    名称:
    基于伍德沃德试剂K且具有不同目标选择性的基于活动的蛋白质组分析探针
    摘要:
    伍德沃德试剂K(WRK)是一种反应性杂环化合物,已用于蛋白质化学中,以共价和非特异性方式标记亲核氨基酸(特别是组氨酸和半胱氨酸)上的蛋白质。我们已经开发了一组基于WRK的基于活性的探针,并显示出令人惊讶和出乎意料的是,这些探针对人类蛋白质组中的几种蛋白质具有相当的选择性。WRK衍生的探针在巨噬细胞迁移抑制因子(MIF)中显示出对催化N末端脯氨酸的独特反应性,可用于标记并(如果配备了荧光团)在活细胞中成像MIF活性。
    DOI:
    10.1002/anie.201602666
点击查看最新优质反应信息

文献信息

  • Harnessing Stereospecific <i>Z</i>-Enamides through Silver-Free Cp*Rh(III) Catalysis by Using Isoxazoles as Masked Electrophiles
    作者:Suvankar Debbarma、Sourav Sekhar Bera、Modhu Sudan Maji
    DOI:10.1021/acs.orglett.8b04130
    日期:2019.2.1
    The stereospecific synthesis of Z-enamides is described in this paper. For the first time, isoxazoles have been employed as electrophiles in C–H functionalization to afford thermodynamically less stable Z-enamides utilizing salicylaldehydes in an atom- and step-economic fashion. The stereochemistry of enamides might originate from the relative disposition of atoms present in isoxazole and the intramolecular
    本文描述了Z-烯酰胺的立体有择合成。首次将异恶唑用作C–H功能化过程中的亲电子试剂,从而以原子经济和分步经济的方式利用水杨醛提供热力学上较不稳定的Z-酰胺。烯酰胺的立体化学可能源自异恶唑中存在的原子的相对位置和分子内氢键。由于多种结构上和电子上不同的水杨醛异恶唑能有效反应,因此该反应显示出极好的范围。
  • [EN] 5-SUBSTITUTED IMINOTHIAZINES AND THEIR MONO-AND DIOXIDES AS BACE INHIBITORS,COMPOSITIONS,AND THEIR USE<br/>[FR] IMINOTHIAZINES 5-SUBSTITUÉES ET LEUR MONOXYDES ET DIOXYDES COMME INHIBITEURS DE BACE, LEURS COMPOSITIONS ET LEUR UTILISATION
    申请人:SCHERING CORP
    公开号:WO2012139425A1
    公开(公告)日:2012-10-18
    The present invention discloses certain iminothiazine compounds and mono- and dioxides thereof, including compounds Formula (I): and tautomers and stereoisomers thereof, and pharmaceutically acceptable salts of said compounds, said tautomers and said stereoismers, wherein each of variables shown in the formula are as defined herein. The compounds of the invention may be useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and uses, including Alzheimer's disease, are also disclosed.
    本发明揭示了某些咪唑啉化合物及其单体和二氧化物,包括化合物Formula (I):及其互变异构体和立体异构体,以及所述化合物、所述互变异构体和所述立体异构体的药用盐,其中公式中显示的各变量如本文所定义。本发明的化合物可能作为BACE抑制剂,用于治疗和预防与之相关的各种病理。还公开了包括一种或多种这样的化合物(单独和与一种或多种其他活性剂组合)的药物组合物,以及它们的制备和用途方法,包括阿尔茨海默病。
  • A novel synthesis of 5-substituted isoxazoles from propargylic amines and N -hydroxyphthalimide
    作者:Yicheng Zhang、Wei Chen、Xueshun Jia
    DOI:10.1016/j.tetlet.2018.04.062
    日期:2018.5
    A mild and efficient method for the synthesis of 5-substituted isoxazoles through cyclization of propargylic amines with N-hydroxyphthalimide (NHPI) under metal-free conditions was developed.
    开发了一种温和有效的方法,该方法通过在无属条件下用N-羟基邻苯二甲酰亚胺(NHPI)环化炔丙基胺来合成5-取代的异恶唑
  • Pyrrolopyrazine kinase inhibitors
    申请人:Bamberg Joe Timothy
    公开号:US20100267666A1
    公开(公告)日:2010-10-21
    The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables Q 1 , R, and X are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.
    本发明涉及一种新型吡咯吡嗪生物的使用,其化学式为I,其中变量Q1、R和X的定义如下所述,该化合物抑制JAK和SYK,并且对于治疗自身免疫和炎症性疾病有用。
  • 5-SUBSTITUTED IMINOTHIAZINES AND THEIR MONO- AND DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE
    申请人:Wu Wen-Lian
    公开号:US20140128382A1
    公开(公告)日:2014-05-08
    The present invention discloses certain iminothiazine compounds and mono- and dioxides thereof, including compounds Formula (I): and tautomers and stereoisomers thereof, and pharmaceutically acceptable salts of said compounds, said tautomers and said stereoisomers, wherein each of variables shown in the formula are as defined herein. The compounds of the invention may be useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and uses, including Alzheimer's disease, are also disclosed.
    本发明揭示了某些亚胺噻唑化合物及其单体和二氧化物,包括化合物公式(I):及其互变异构体和立体异构体,以及所述化合物、所述互变异构体和所述立体异构体的药学上可接受的盐,其中公式中所示的每个变量如本文所定义。本发明的化合物可用作BACE抑制剂和/或用于治疗和预防与之相关的各种病理学。本发明还揭示了包括一种或多种此类化合物(单独和与一种或多种其他活性剂组合)的制药组合物,以及其制备和用途的方法,包括阿尔茨海默病。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫